Novartis plans to open a new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indiana,USA.
The 70,000-square foot site dedicated to RLT manufacturing stands as the world's foremost and most cutting-edge facility of its kind.
The Indianapolis site marks the next era in RLT manufacturing growth, ensuring substantial supply expansions for the foreseeable future with this new addition.
With four active manufacturing facilities, and boasting an RLT production capacity of 250,000 doses in 2024 and beyond, the company persists in broadening its global RLT manufacturing network. Ongoing clinical trials hold promise, potentially extending the accessibility of Pluvicto and Lutathera to more patients in earlier stages of treatment.
This purpose-built facility is tailored specifically for the present and future production of RLTs. Its design incorporates provisions for ongoing line expansion, earmarking areas for the implementation of fully automated lines—a pioneering initiative within the radiopharmaceutical industry.
The site is poised to meet the rising demand from patients in the US and, upon approval, will extend its services to cater to the needs of patients in Canada.
The facility is expected to be opened in 2024.
Type New Construction